Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease
OPEN Pituitary | 7 Nov 2015
M Fleseriu, R Pivonello, J Young, AH Hamrahian, ME Molitch, C Shimizu, T Tanaka, A Shimatsu, T White, A Hilliard, C Tian, N Sauter, BM Biller and X Bertagna
In a 10-week proof-of-concept study (LINC 1), the potent oral 11β-hydroxylase inhibitor osilodrostat (LCI699) normalized urinary free cortisol (UFC) in 11/12 patients with Cushing’s disease. The current 22-week study (LINC 2; NCT01331239) further evaluated osilodrostat in patients with Cushing’s disease.
* Data courtesy of Altmetric.com